E.i. Dupont De Nemours and Company

The Dupont Merck Pharmaceutical Company

Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Dupont Pharmaceuticals Company

Wyeth

Dupont Pharmaceuticals, Inc.

Ronald L Magolda

James M Trzaskos

Carl P Decicco

Irina Cipora Jacobson

Douglas G Batt

William John Pitts

Michael J Orwat

Timothy C Burn

Carl Henry Behrens

Micky Daniel Tortorella

Robert A Copeland

Elizabeth C Arner

Ruiqin Liu

Michael A Pratta

Fude Yang

Kimberly A Solomon

Paul R Johnson

Soo Sung Ko

James L Gaylor

Simon H Stam

John Anthony Butera

Jingwu Duan

Robert J Cherney

Eugene John Trybulski

Gregory Scott Welmaker

Pasquale N Confalone

Xiaohua He

Matthew A Wilson

Stephen W Wright

Chu-Bio Xue

Elizabeth Arner

David Nelson

The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.

Tetracyclic indoles as potassium channel modulators

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu-Ala. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.

Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using same

The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu -Ala . The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.

Aggrecan degrading metallo proteases

Nucleic acids encoding aggrecan degrading metallo proteases

This invention relates to macrocyclic molecules which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation and inhibitors of the release of tumor necrosis factor. The present invention also relates to pharmaceutical compositions comprising such compounds and to methods of using these compounds for the treatment of inflammatory diseases.

Macrocyclic compounds as metalloprotease inhibitors

This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.

Carbocyclic heterocyclic fused-ring quinolinecarboxylic acids useful as

Carbocyclic and hetertocyclic fused-ring quinolinecarboxylic acids

Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful

Carbocyclic fused-ring quinolinecarboxylic acids useful as

The present invention relates to vinylogous hydroxamic acids, processes for their manufacture, pharmaceutical preparations containing them, and their use in the treatment of various disorders.

Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase

Lanosterols substituted in the 14 and/or 15 position(s) which are active in inhibiting lanosta-8,24-dien-3.beta.-ol 14.alpha.-methyl-demethylase activity, suppressing 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity, decreasing cholesterol synthesis and reducing serum cholesterol levels are disclosed.

Steroid derivatives useful as hypocholesterolemics

1-Thioether-1-acylaminophosphatidylcholine compounds are structural analogs of platelet activating factor and useful for inhibition of phospholipase A.sub.2, reduction of blood pressure, and alleviation of inflammation.

Analogs of platelet activating factor

Growing community of inventors

Wallingford, PA, United States of America

Ronald L Magolda